These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22883664)

  • 1. [New challenges of HER2 testing in breast cancer].
    Yang F; Yang WT; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):289-92. PubMed ID: 22883664
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients.
    Kokate P; Sawaimoon S; Bhatia S; Mandava S
    Genet Test Mol Biomarkers; 2012 Apr; 16(4):239-45. PubMed ID: 22023243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
    Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 Immunohistochemistry-Guided Targeted Fluorescence In Situ Hybridization Analysis Does Not Help Identify Intratumoral Heterogeneity in Breast Cancer.
    Gulbahce HE; Factor R; Geiersbach K; Downs-Kelly E
    Arch Pathol Lab Med; 2016 Aug; 140(8):741. PubMed ID: 27472230
    [No Abstract]   [Full Text] [Related]  

  • 9. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
    Shen DH; Wang FH; Yu YZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
    Zhu X; Lu Y; Lu H; Yang W; Tu X; Cai X; Zhou X
    Hum Pathol; 2011 Oct; 42(10):1499-504. PubMed ID: 21676436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL; Jamehdor MR; Arber JM
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
    Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
    Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of HER2 gene expression status in breast cancer by fluorescence in-situ hybridization].
    Zeng X; Zhao DC; Zhou WX; Wu SF; Liang ZY; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):701-5. PubMed ID: 16536311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [To improve the quality of pathologic diagnosis through standardized HER2 testing].
    Bu H; Yang W
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):217-8. PubMed ID: 24915808
    [No Abstract]   [Full Text] [Related]  

  • 15. INTERLABORATORY CONCORDANCE IN HER-2 POSITIVE BREAST CANCER.
    Jonjić N; Mustać E; Tomić S; Razumović JJ; Sarcević B; Blazicević V; Labinac LP; Svagelj D; Kopjar A; Sikić NL; Vrbicić B; Borić I
    Acta Clin Croat; 2015 Dec; 54(4):479-85. PubMed ID: 27017723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
    Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
    J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance.
    Yang YL; Fan Y; Lang RG; Gu F; Ren MJ; Zhang XM; Yin D; Fu L
    Breast Cancer Res Treat; 2012 Aug; 134(3):1095-102. PubMed ID: 22476857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy.
    Ballinger TJ; Sanders ME; Abramson VG
    Clin Breast Cancer; 2015 Jun; 15(3):171-80. PubMed ID: 25516402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.
    Lambein K; Praet M; Forsyth R; Van den Broecke R; Braems G; Matthys B; Cocquyt V; Denys H; Pauwels P; Libbrecht L
    J Clin Pathol; 2011 Mar; 64(3):200-7. PubMed ID: 21177747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Guidelines for HER2 detection in breast cancer, the 2014 version].
    Guideline Recommendations for HER2 Detection in Breast Cancer Group
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):262-7. PubMed ID: 24915819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.